Radnor Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Radnor Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-13,332	Closed	-$84K	–	252
2022 Q1	$84K	Hold	13,332	–	–	0.02%	240
2021 Q4	$52K	Buy	+13,332	New	+$57.9K	0.01%	245

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Radnor Capital Management's MACK Position: Q2 2022 in Review

Radnor Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2022, closing a stake of 13,332 shares — an estimated $84K sold.

Radnor Capital Management first reported a position in MACK in Q4 2021 and held it in 2 quarters. The position peaked at $84K in Q1 2022. 43 funds tracked by Wall St. Rank hold MACK as of Q2 2022.

Radnor Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
Radnor Capital Management sold 13,332 Merrimack Pharmaceuticals, Inc. shares in Q2 2022, an estimated $84K.
Radnor Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2021 and held it in 2 quarters.
Radnor Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $84K in Q1 2022.
43 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2022.

Based on Radnor Capital Management's 13F filing for Q2 2022, filed 11 Jul 2022.